Bris­tol My­er­s' TYK2 drug bombs ul­cer­a­tive col­i­tis test, but hopes are still high with pso­ri­a­sis fil­ing on deck

2 weeks ago
R&D

Em­bold­ened by a pos­i­tive PhI­II, No­var­tis steers a late-stage BTK in­hibitor in­to a piv­otal MS tri­al

2 weeks ago
R&D

UP­DAT­ED: With a fresh $75M, Michael Ehler­s' lat­est take on non-vi­ral gene ther­a­py is ready for take­off

2 weeks ago
Financing

ARCH un­veils its Re­al­ly Big Neu­ro­science Com­pa­ny with $500M, an Am­gen deal and eyes on de­pres­sion, Alzheimer's and a lot more

2 weeks ago
Financing
Startups

Break­ing: Pfiz­er de­vel­op­ment chief Rod MacKen­zie is re­tir­ing af­ter a lengthy ca­reer capped by his­toric suc­cess

3 weeks ago
People

UP­DAT­ED: A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

3 weeks ago
Pharma

Take­da flash­es red light on 'break­through' nar­colep­sy drug af­ter PhII tri­als turned up mys­te­ri­ous safe­ty sig­nal

3 weeks ago
R&D

Trou­bled Voy­ager’s gene ther­a­py re­launch gets a boost with $630M Pfiz­er deal

3 weeks ago
Deals
Cell/Gene Tx

Af­ter a brief stint in the top can­cer re­search spot at Gilead, Va­le­ria Fan­tin jumps over to Sanofi

3 weeks ago
People
Pharma

A year in­to SPAC merg­er, Gem­i­ni re­struc­tures pipeline with 20% of staff, lead­er­ship on the chop­ping block

3 weeks ago
People
R&D

Glax­o­SmithK­line aban­don­ing icon­ic US HQ space in a shift in­spired by the new nor­mal

3 weeks ago
Pharma

UP­DAT­ED: Long­time NIH di­rec­tor Fran­cis Collins re­signs to make room for 'new vi­sion'

3 weeks ago
People

New small mol­e­cule play­er with roots in David Li­u's lab col­lects an­oth­er $78M to fu­el search for ex­osites

3 weeks ago
Financing

Bio­Marin re­cruits Ver­tex's trans­la­tion­al chief to head up clin­i­cal tri­al ops

3 weeks ago
People

Enan­ta culls in­ter­nal NASH work, bet­ting on an out-li­cens­ing strat­e­gy in the dis­as­ter-strewn field

3 weeks ago
R&D

J&J signs on Xen­cor for a $100M li­cens­ing deal tar­get­ing CD20, look­ing to press its ad­van­tage in bis­pecifics

3 weeks ago
Deals
R&D

J&J re­leas­es the first big da­ta cut in the RSV vac­cine race, set­ting bar for Glax­o­SmithK­line and Pfiz­er

3 weeks ago
R&D

IPOs get back in­to gear with fil­ings from Lian­Bio and Xilio, and Cor­moran­t's SPAC has a deal

3 weeks ago
Financing

Mer­ck shakes hands with Ac­celeron; Fi­nal­ly, a pill for Covid-19; The past and fu­ture of con­tract re­search; and more

3 weeks ago
Weekly

UP­DAT­ED: Unit­ed Ther­a­peu­tics tran­si­tions to pub­lic ben­e­fit cor­po­ra­tion more than 20+ years af­ter IPO

3 weeks ago
Pharma

Avoro Cap­i­tal, the deal killer be­hind the Seagen-Im­munomedics blowup, has turned its eyes on Mer­ck­'s Ac­celeron buy­out

3 weeks ago
Pharma

Mer­ck claims pan­dem­ic break­through: Covid-19 pill re­duces hos­pi­tal­iza­tion and death by 50%

3 weeks ago
R&D
Coronavirus

Cat­a­lyst wins re­ver­sal in or­phan ex­clu­siv­i­ty court bat­tle with FDA

3 weeks ago
Pharma
FDA+

Fresh off a big pan­dem­ic year, Ther­mo Fish­er an­nounces more growth at its Mid­west hub

3 weeks ago
Manufacturing
First page Previous page 123456 Next page Last page